share_log

ReShape Lifesciences Expects 2024 Operating Expenses To Decrease By More Than 50% Compared to 2023; Reaffirming Commitment To Profitability

ReShape Lifesciences Expects 2024 Operating Expenses To Decrease By More Than 50% Compared to 2023; Reaffirming Commitment To Profitability

ReShape Lifesciences預計，與2023年相比，2024年的運營支出將減少50％以上；重申對盈利的承諾
Benzinga ·  04/02 04:09

ReShape Lifesciences Expects 2024 Operating Expenses To Decrease By More Than 50% Compared to 2023; Reaffirming Commitment To Profitability

ReShape Lifesciences預計，與2023年相比，2024年的運營支出將減少50％以上；重申對盈利的承諾

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論